Analysts Expect Tricida, Inc. (NASDAQ:TCDA) to Post -$0.53 Earnings Per Share

Equities research analysts expect that Tricida, Inc. (NASDAQ:TCDAGet Rating) will announce earnings of ($0.53) per share for the current quarter, Zacks reports. Zero analysts have issued estimates for Tricida’s earnings. The lowest EPS estimate is ($0.56) and the highest is ($0.50). Tricida posted earnings per share of ($0.67) in the same quarter last year, which would suggest a positive year-over-year growth rate of 20.9%. The business is expected to issue its next earnings results on Monday, January 1st.

According to Zacks, analysts expect that Tricida will report full-year earnings of ($2.12) per share for the current financial year, with EPS estimates ranging from ($2.20) to ($2.04). For the next year, analysts anticipate that the company will report earnings of ($0.94) per share, with EPS estimates ranging from ($1.90) to $0.03. Zacks Investment Research’s EPS averages are a mean average based on a survey of research firms that that provide coverage for Tricida.

Tricida (NASDAQ:TCDAGet Rating) last announced its quarterly earnings results on Tuesday, March 29th. The company reported ($0.92) EPS for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.21). During the same quarter in the prior year, the company earned ($1.09) earnings per share.

Several equities research analysts have recently issued reports on TCDA shares. Needham & Company LLC reaffirmed a “buy” rating and issued a $18.00 price objective (down from $20.00) on shares of Tricida in a research note on Wednesday, March 30th. Zacks Investment Research lowered Tricida from a “buy” rating to a “hold” rating in a research note on Thursday, January 20th. Finally, The Goldman Sachs Group started coverage on Tricida in a research note on Tuesday, April 12th. They issued a “buy” rating and a $25.00 price objective for the company.

In related news, major shareholder Brian M. Isern sold 11,804 shares of the firm’s stock in a transaction that occurred on Thursday, April 28th. The stock was sold at an average price of $10.61, for a total transaction of $125,240.44. Following the completion of the sale, the insider now directly owns 770,496 shares of the company’s stock, valued at approximately $8,174,962.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 47.40% of the stock is currently owned by company insiders.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in Tricida by 92.2% during the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,270 shares of the company’s stock worth $27,000 after purchasing an additional 1,569 shares during the period. Dorsey Wright & Associates purchased a new position in shares of Tricida in the 1st quarter valued at $30,000. BlackRock Inc. increased its holdings in shares of Tricida by 0.5% in the 1st quarter. BlackRock Inc. now owns 965,743 shares of the company’s stock valued at $7,937,000 after acquiring an additional 4,966 shares during the period. Quantbot Technologies LP purchased a new position in shares of Tricida in the 1st quarter valued at $45,000. Finally, PDT Partners LLC increased its holdings in shares of Tricida by 34.5% in the 1st quarter. PDT Partners LLC now owns 24,600 shares of the company’s stock valued at $202,000 after acquiring an additional 6,304 shares during the period. Institutional investors own 79.28% of the company’s stock.

Tricida stock traded down $0.41 during midday trading on Wednesday, reaching $9.59. 4,997 shares of the stock traded hands, compared to its average volume of 546,576. The stock’s fifty day moving average is $9.12 and its 200-day moving average is $8.66. Tricida has a 12 month low of $3.55 and a 12 month high of $12.45. The stock has a market cap of $531.48 million, a P/E ratio of -3.34 and a beta of 0.91. The company has a quick ratio of 5.12, a current ratio of 5.12 and a debt-to-equity ratio of 584.92.

Tricida Company Profile (Get Rating)

Tricida, Inc operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track.

Read More

Get a free copy of the Zacks research report on Tricida (TCDA)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Tricida Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tricida and related companies with's FREE daily email newsletter.